__NUXT_JSONP__("/drugs/Mitoxantrone_Hydrochloride", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:"mitoXANTRONE",indication:"INDICATIONS AND USAGE Mitoxantrone injection USP (concentrate) is indicated for reducing neurologic disability and\u002For the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone injection USP (concentrate) is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone injection USP (concentrate) in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone injection USP (concentrate) in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.",manufacturer:"Teva Parenteral Medicines, Inc.",splSetId:"4d0f0f1a-31af-40fa-9c64-e90891fa6ce4"},{brand:b,indication:"INDICATIONS AND USAGE Mitoxantrone is indicated for reducing neurologic disability and\u002For the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.",manufacturer:"Hospira, Inc.",splSetId:"accf9569-4b57-4e83-a7db-4e890a75d1ba"},{brand:b,indication:"INDICATIONS AND USAGE: Mitoxantrone Injection, USP is indicated for reducing neurologic disability and\u002For the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.",manufacturer:"Fresenius Kabi USA, LLC",splSetId:"fcb8ef8a-f770-4416-8fc5-fa01d98c8eee"}],id:a,nciThesaurus:{casRegistry:"70476-82-3",chebiId:"CHEBI:50727",chemicalFormula:"C22H28N4O6.2HCl",definition:"The hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.",fdaUniiCode:"U6USW86RD0",identifier:"C665",preferredName:c,semanticType:"Antibiotic",subclassOf:["C253"],synonyms:["1,3-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione Dihydrochloride","1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone Dihydrochloride","CL 232315","DHAD","DHAQ","Dihydroxyanthracenedione Dihydrochloride","MITOXANTRONE HYDROCHLORIDE","Mitoxantrone Dihydrochloride",c,"Mitoxantroni Hydrochloridum","Mitozantrone Hydrochloride","Mitroxone","Neotalem","Novantrone","Onkotrone","Pralifan"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FMitoxantrone_Hydrochloride",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Mitoxantrone_Hydrochloride","Mitoxantrone","Mitoxantrone Hydrochloride","2021-10-30T13:42:53.903Z")));